KeyBank National Association’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

KeyBank National Association’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-15,250	Closed	-$1.55M	–	1081
2023 Q2	$1.55M	Hold	15,250	–	–	0.01%	409
2023 Q1	$1.39M	Hold	15,250	–	–	0.01%	420
2022 Q4	$579K	Hold	15,250	–	–	﹤0.01%	639
2022 Q3	$383K	Hold	15,250	–	–	﹤0.01%	750
2022 Q2	$463K	Hold	15,250	–	–	﹤0.01%	698
2022 Q1	$500K	Buy	+15,250	New	+$453K	﹤0.01%	730
2021 Q4	–	Sell	-10,000	Closed	-$1.01M	–	1109
2021 Q3	$1.01M	Hold	10,000	–	–	﹤0.01%	556
2021 Q2	$1.42M	Buy	10,000 +2,000	+25%	+$226K	0.01%	453
2021 Q1	$798K	Buy	8,000 +2,000	+33%	+$233K	﹤0.01%	657
2020 Q4	$742K	Buy	+6,000	New	+$788K	﹤0.01%	634

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

KeyBank National Association's RETA Position: Q3 2023 in Review

KeyBank National Association sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 15,250 shares — an estimated $1.55M sold.

KeyBank National Association first reported a position in RETA in Q4 2020 and held it in 10 quarters. The position peaked at $1.55M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

KeyBank National Association reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
KeyBank National Association sold 15,250 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.55M.
KeyBank National Association first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 10 quarters.
KeyBank National Association's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.55M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on KeyBank National Association's 13F filing for Q3 2023, filed 8 Nov 2023.